Eli LillyLLY
LLY
About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Employees: 43,000
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
115% more first-time investments, than exits
New positions opened: 245 | Existing positions closed: 114
12% more repeat investments, than reductions
Existing positions increased: 1,530 | Existing positions reduced: 1,371
2% more funds holding
Funds holding: 3,499 [Q2] → 3,585 (+86) [Q3]
1.74% less ownership
Funds ownership: 85.62% [Q2] → 83.88% (-1.74%) [Q3]
6% less capital invested
Capital invested by funds: $736B [Q2] → $694B (-$42.7B) [Q3]
12% less call options, than puts
Call options by funds: $9.4B | Put options by funds: $10.7B
15% less funds holding in top 10
Funds holding in top 10: 543 [Q2] → 461 (-82) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$975
34%
upside
Avg. target
$1,056
46%
upside
High target
$1,250
72%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Tim Anderson 67% 1-year accuracy 4 / 6 met price target | 37%upside $997 | Buy Reinstated | 10 Dec 2024 |
Wolfe Research Alexandria Hammond 33% 1-year accuracy 3 / 9 met price target | 38%upside $1,000 | Outperform Initiated | 15 Nov 2024 |
Deutsche Bank James Shin 0% 1-year accuracy 0 / 4 met price target | 40%upside $1,015 | Buy Maintained | 4 Nov 2024 |
Barclays Carter Gould 35% 1-year accuracy 13 / 37 met price target | 34%upside $975 | Overweight Maintained | 31 Oct 2024 |
B of A Securities Geoff Meacham 41% 1-year accuracy 11 / 27 met price target | 52%upside $1,100 | Buy Maintained | 31 Oct 2024 |
Financial journalist opinion
Based on 122 articles about LLY published over the past 30 days
Positive
The Motley Fool
1 day ago
Should You Buy the Dip in Eli Lilly Stock Right Now?
2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (LLY -4.21%). At one point, share prices had gained as much as 65% on the year.
Neutral
The Motley Fool
1 day ago
Eli Lilly Missed Sales Expectations Again. Should Investors Be Worried?
In the first half of 2024, it seemed Eli Lilly (LLY -4.21%) could do no wrong. Unfortunately, the good times didn't last very long.
Positive
The Motley Fool
2 days ago
3 Unstoppable Stocks to Buy in 2025
You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong underlying business prospects that they're practically unstoppable.
Negative
The Motley Fool
2 days ago
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (LLY -4.21%) Mounjaro skyrocketing over the past year. However, Eli Lilly recently surprised investors when it cut its full-year revenue guidance ahead of an investor conference after sales of its GLP-1 drugs fell short of expectations.
Neutral
CNBC Television
3 days ago
Dr. Kavita Patel talks impact of GLP-1 price negotiations
Dr. Kavita Patel joins 'Fast Money' to talk what is next for GLP-1 drug makers.
Negative
Fox Business
3 days ago
Ozempic, Wegovy among drugs subject to Medicare price controls
The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.
Positive
The Motley Fool
3 days ago
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Being a long-term investor brings a unique peace of mind. It requires thinking in decades, not months or years, which allows an investor to focus on owning exceptional businesses.
Positive
The Motley Fool
3 days ago
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?
Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's largest healthcare company, with a market cap that topped $860 billion at one point.
Positive
Zacks Investment Research
4 days ago
FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition
FDA approves Lilly's Omvoh for Crohn's disease, expanding its use to the second major type of IBD condition.
Positive
The Motley Fool
4 days ago
My 10 Top Stocks to Buy to Start the New Year Off Right
Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double digits. Investor enthusiasm about technology and growth stocks, and the economic environment ahead, drove the momentum.
Charts implemented using Lightweight Charts™